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Background: Drug-eluting stents have reduced the need for target lesion revascularization (TLR) caused by in-stent restenosis (IRS). At the same 
time, the relative importance of stent thrombosis as a cause of TLR has become more evident. We evaluated the quantitative relationship and the 
clinical presentation between IRS and stent thrombosis as a cause for TLR in patients treated with percutaneous coronary intervention (PCI) and 
drug-eluting (DES) or bare metal (BMS) stent implantations in Western Denmark.
Methods: From January 2002 to June 2005 all consecutive patients, who had DES or BMS implantation where identified in the population based 
Western Denmark Heart Registry. Of these patients we identified all patients having TLR within the first 12 months after index PCI.
Results: A total of 12,374 patients were treated: 3,516 with DES and 8,858 with BMS. TLR was performed in 652 (5.3%) patients <12 months 
after index PCI (DES 134 (3.8%) and BMS 517 (5.8)). IRS was seen in 533 patients, corresponding to 81.7% of all TLRs, (DES 102 (3.0%) and BMS 
438 (5.0%)) and angiographic confirmed stent thrombosis was seen in 119 patients (DES 32 (0.9%) and BMS 87 (1.0%).
Patients with IRS were admitted due to non-ST segment elevation myocardial infarction (nonSTEMI) (n=39 (7.3%) [DES 7.9% vs. BMS 7.2%] 
unstable angina (UAP) (n=61 (11.4%) [DES 5.9% vs. 12.6%] or stable angina pectoris (SAP) (n=430 (81.7%) [DES 86.1% vs. BMS 80.1%], p=0.163. 
Patients with angiographic confirmed stent thrombosis were treated due to STEMI (n=105 (88.2%) [DES 84.4% vs. BMS 89.7%], nonSTEMI (n=10 
(8.4%) [DES 9.4% vs. BMS 8.0%] or UAP (n=4 (3.3%) [DES 6.3% vs. BMS 2.3%], p=0.546 (between DES and BMS).
Conclusion: Angiographic confirmed stent thrombosis constituted 18% of all TLR. Of these patients, 97% presented clinically as myocardial 
infarction, whereas only 7% did that in the IRS group. The clinical presentation of the event was not different in the BMS or DES treated patients.
